Scottish Startup 1nhaler Secures £2.2Mn to Advance Its Innovative Cardboard Inhaler

The funding round was led by Archangels, with support from Scottish Enterprise and BBB Investments.

The investment will help the company complete the development of its main product, 1nhaler Salbutamol. It combines the company's new inhaler device with salbutamol, a commonly used medicine for treating asthma.

The funding will also support the transfer of the product to a contract manufacturer, which will produce materials for clinical trials. The company plans to conduct a small clinical trial to gather the data needed for regulatory approval, which it is targeting for late 2027.

In addition, 1nhaler will work with manufacturing specialist Harro Höfliger to study how to scale up production of its dry powder inhaler (DPI). The funding will also help the team develop business partnerships with companies interested in its inhaler technology and lead product.

Lisa McMyn, co-founder and Chief Executive Officer at 1nhaler, said: Lisa McMyn, co-founder and Chief Executive Officer at 1nhaler, said: “This investment takes us to one of the most important milestones in our journey – taking our own lead product into the clinic. The continued backing of Archangels, Scottish Enterprise and BBB Investments reflects the technical and commercial progress we have made over the past year.”

Dr Sarah Hardy, Director and Head of New Investments at Archangels, said: “Having backed 1nhaler since 2023, we see this latest round as a reflection of our confidence in the team and its novel inhaler device that has the potential to disrupt the global market for inhaled medicines. We are particularly excited by the commercial traction and interest from potential partners across a broader range of drugs than we initially anticipated, highlighting the platform’s versatility and market potential. Taking this product into a clinical study is a significant milestone towards demonstrating its performance in patients. Working alongside our co-investors, we look forward to supporting 1nhaler through its next stage of growth as it builds towards regulatory approval and commercialisation.”

Derek Shaw, Director of Company Funding and Investment at Scottish Enterprise, said: ‘This investment highlights our dedication to supporting the growth of ambitious businesses in Scotland. By helping these companies scale, we aim to empower them to compete and lead in global markets. Scotland has distinct global strengths in industries such as human health and fostering the development of companies such as 1nhaler is key to sustaining their success and driving future growth.’

1nhaler Ltd is a Scotland-based company developing a new type of inhaler for delivering medicines. Its device is a single-use, dry-powder inhaler that does not use propellants and is made mainly from cardboard. It also uses a patented membrane-based system to deliver the medicine.

The inhaler starts as a flat, credit-card-sized shape and folds into a 3D device when needed. It is designed to be easy to use, carry and manufacture. Its cardboard-based design could also help reduce the environmental impact compared with traditional inhalers.

Read Also- Tumbleweed Raises €6.9Mn in Austria’s Largest-Ever Spacetech Seed Funding Round